FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034960937> ?p ?o ?g. }

• W2034960937 endingPage "e174" @default.
• W2034960937 startingPage "e174" @default.
• W2034960937 abstract "Recent reports underscore the unparalleled potential of antisense-oligonucleotide (ASO)-based approaches to ameliorate various pathological conditions. However, in vivo studies validating the effectiveness of a short ASO (<10-mer) in the context of a human disease have not been performed. One disease with proven amenability to ASO-based therapy is spinal muscular atrophy (SMA). SMA is a neuromuscular disease caused by loss-of-function mutations in the survival motor neuron 1 (SMN1) gene. Correction of aberrant splicing of the remaining paralog, SMN2, can rescue mouse models of SMA. Here, we report the therapeutic efficacy of an 8-mer ASO (3UP8i) in two severe models of SMA. While 3UP8i modestly improved survival and function in the more severe Taiwanese SMA model, it dramatically increased survival, improved neuromuscular junction pathology, and tempered cardiac deficits in a new, less severe model of SMA. Our results expand the repertoire of ASO-based compounds for SMA therapy, and for the first time, demonstrate the in vivo efficacy of a short ASO in the context of a human disease. Recent reports underscore the unparalleled potential of antisense-oligonucleotide (ASO)-based approaches to ameliorate various pathological conditions. However, in vivo studies validating the effectiveness of a short ASO (<10-mer) in the context of a human disease have not been performed. One disease with proven amenability to ASO-based therapy is spinal muscular atrophy (SMA). SMA is a neuromuscular disease caused by loss-of-function mutations in the survival motor neuron 1 (SMN1) gene. Correction of aberrant splicing of the remaining paralog, SMN2, can rescue mouse models of SMA. Here, we report the therapeutic efficacy of an 8-mer ASO (3UP8i) in two severe models of SMA. While 3UP8i modestly improved survival and function in the more severe Taiwanese SMA model, it dramatically increased survival, improved neuromuscular junction pathology, and tempered cardiac deficits in a new, less severe model of SMA. Our results expand the repertoire of ASO-based compounds for SMA therapy, and for the first time, demonstrate the in vivo efficacy of a short ASO in the context of a human disease." @default.
• W2034960937 created "2016-06-24" @default.
• W2034960937 creator A5003781254 @default.
• W2034960937 creator A5061593500 @default.
• W2034960937 creator A5081637944 @default.
• W2034960937 creator A5086288935 @default.
• W2034960937 creator A5087950892 @default.
• W2034960937 creator A5089777195 @default.
• W2034960937 date "2014-01-01" @default.
• W2034960937 modified "2023-10-03" @default.
• W2034960937 title "A Short Antisense Oligonucleotide Ameliorates Symptoms of Severe Mouse Models of Spinal Muscular Atrophy" @default.
• W2034960937 cites W1554872850 @default.
• W2034960937 cites W1931248805 @default.
• W2034960937 cites W1968479063 @default.
• W2034960937 cites W1980477780 @default.
• W2034960937 cites W1980922145 @default.
• W2034960937 cites W1983082063 @default.
• W2034960937 cites W1997761582 @default.
• W2034960937 cites W2000725203 @default.
• W2034960937 cites W2007404424 @default.
• W2034960937 cites W2024685343 @default.
• W2034960937 cites W2028920559 @default.
• W2034960937 cites W2029827355 @default.
• W2034960937 cites W2034784666 @default.
• W2034960937 cites W2037788145 @default.
• W2034960937 cites W2039297214 @default.
• W2034960937 cites W2045951351 @default.
• W2034960937 cites W2046392396 @default.
• W2034960937 cites W2049273201 @default.
• W2034960937 cites W2054380003 @default.
• W2034960937 cites W2056669656 @default.
• W2034960937 cites W2067161603 @default.
• W2034960937 cites W2068230814 @default.
• W2034960937 cites W2070086105 @default.
• W2034960937 cites W2077548086 @default.
• W2034960937 cites W2081384639 @default.
• W2034960937 cites W2085465310 @default.
• W2034960937 cites W2092679887 @default.
• W2034960937 cites W2095373803 @default.
• W2034960937 cites W2103017827 @default.
• W2034960937 cites W2107257806 @default.
• W2034960937 cites W2107277218 @default.
• W2034960937 cites W2119330162 @default.
• W2034960937 cites W2121396879 @default.
• W2034960937 cites W2125887220 @default.
• W2034960937 cites W2132110012 @default.
• W2034960937 cites W2132519155 @default.
• W2034960937 cites W2133380348 @default.
• W2034960937 cites W2133814931 @default.
• W2034960937 cites W2136930242 @default.
• W2034960937 cites W2137021233 @default.
• W2034960937 cites W2142120640 @default.
• W2034960937 cites W2147566918 @default.
• W2034960937 cites W2152766938 @default.
• W2034960937 cites W2153726984 @default.
• W2034960937 cites W2156695025 @default.
• W2034960937 cites W2160696072 @default.
• W2034960937 cites W2163655775 @default.
• W2034960937 cites W2167025898 @default.
• W2034960937 cites W2167790027 @default.
• W2034960937 cites W2170780799 @default.
• W2034960937 cites W2192080449 @default.
• W2034960937 doi "https://doi.org/10.1038/mtna.2014.23" @default.
• W2034960937 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4121513" @default.
• W2034960937 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25004100" @default.
• W2034960937 hasPublicationYear "2014" @default.
• W2034960937 type Work @default.
• W2034960937 sameAs 2034960937 @default.
• W2034960937 citedByCount "45" @default.
• W2034960937 countsByYear W20349609372014 @default.
• W2034960937 countsByYear W20349609372015 @default.
• W2034960937 countsByYear W20349609372016 @default.
• W2034960937 countsByYear W20349609372017 @default.
• W2034960937 countsByYear W20349609372018 @default.
• W2034960937 countsByYear W20349609372019 @default.
• W2034960937 countsByYear W20349609372020 @default.
• W2034960937 countsByYear W20349609372021 @default.
• W2034960937 countsByYear W20349609372022 @default.
• W2034960937 countsByYear W20349609372023 @default.
• W2034960937 crossrefType "journal-article" @default.
• W2034960937 hasAuthorship W2034960937A5003781254 @default.
• W2034960937 hasAuthorship W2034960937A5061593500 @default.
• W2034960937 hasAuthorship W2034960937A5081637944 @default.
• W2034960937 hasAuthorship W2034960937A5086288935 @default.
• W2034960937 hasAuthorship W2034960937A5087950892 @default.
• W2034960937 hasAuthorship W2034960937A5089777195 @default.
• W2034960937 hasBestOaLocation W20349609371 @default.
• W2034960937 hasConcept C104317684 @default.
• W2034960937 hasConcept C111599444 @default.
• W2034960937 hasConcept C11413529 @default.
• W2034960937 hasConcept C142724271 @default.
• W2034960937 hasConcept C151730666 @default.
• W2034960937 hasConcept C161921814 @default.
• W2034960937 hasConcept C169760540 @default.
• W2034960937 hasConcept C2776356578 @default.
• W2034960937 hasConcept C2776752467 @default.
• W2034960937 hasConcept C2778045022 @default.
• W2034960937 hasConcept C2778558090 @default.

• next